Advertisement

Topics

Companies Related to "Study Evaluating ERB-041 in Active Crohn's Disease" [Most Relevant Company Matches] RSS

01:48 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Study Evaluating ERB-041 in Active Crohn's Disease" found in our extensive corporate database of over 50,000 company records.

Showing "Study Evaluating Active Crohn Disease" Companies 1–25 of 4,200+

Extremely Relevant

Crohn'sAdvocate Program

Developed as a support and advocacy program for the half a million Americans affected by Crohn's disease, the Crohn'sAdvocate(TM) program was launched nearly a year ago by UCB. The program takes a 360 degree approach to connecting people with Crohn's disease with experts and Advocates; educating those affected by the condition and empowering the community to take an active part in managing their ...


Crohns & Colitis Foundation of America

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's disease is not known, but the disease is associated with an abnormality of the immune system that could be triggered by viral or bacterial infections, a genetic predisposition or diet. Symptoms of Crohn's ...

Relevant

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...


RMEI Medical Education (RMEI) and Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation (the Foundation) is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The Foundation’s mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundatio...

Crohn's & Colitis Foundation of America

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with approximately 79 cents of every dollar the Foundation spends going to mission-critical programs. The organ...

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

TxCell

TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. It is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of autolo...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Novogen

Novogen's business is in the most pressing area facing medicine in the modern era - that of degenerative diseases and disorders. Cancer Heart disease (stroke, hypertension, coronary artery disease) Osteoporosis Rheumatoid arthritis Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease) Neurological diseases (Parkinson's Disease, motor neurone disease) Autoimmune diseases (m...

Outcomes Pharmaceutical Health Care

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides services and technologies focused on evaluating the safety, effectiveness, and quality of healthcare products and services. The company has designed, developed, and managed an industr...

ImproveCareNow

ImproveCareNow is a not-for-profit alliance of health care providers (including physicians, researchers, nurses, quality improvement experts, statisticians, data processing experts and administrators), patients and families all dedicated to helping children and adolescents with Crohn's disease and ulcerative colitis.

VLST Corp

VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes and obesity. The company has already identified eight novel disease targets and is currently evaluating three of these targets for their therapeu...

Tapestry Pharmaceuticals

Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing. Tapestry's technical expertise is our ability to identify, chemically alter and produce novel therapeutic compounds derived from natural product sources. Tapestry has devel...

Outcome Sciences, Inc.

Outcome is the leading provider of patient registries, studies, quality improvement programs, and integrated technologies for evaluating real-world outcomes. Outcome provides services and technologies focused on evaluating the safety, effectiveness, and quality of healthcare products and services. The company has designed, developed, and managed more than ...

The Crohn's & Colitis Foundation of America

Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

NewEast Biosciences

NewEast Biosciences are specialized in generating protein configuration-specific monoclonal antibodies that recognize active (GTP-bound) G proteins (including Ras-superfamily small GTPases and heterotrimeric G proteins). These unique antibodies do not recognize the inactive (GDP-bound) G proteins. These monoclonal antibodies have been successfully used to immunoprecipitate active G proteins...

The North American Society for the Study of Celiac Disease

Chiasma (Israel), LTD

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the GI wall, portal system and then to the systemic circulation. Chiasma creates its internal pipeline by selecting approved macromolecules that are currently available in injectable form...

SLA Pharma AG

S.L.A. Pharma AG is a privately owned Swiss company pioneering the development of speciality pharmaceutical products for gastrointestinal and rare disorders. Their pipeline consists of Phase II and Phase III developments for indications with unmet clinical needs such as anal fissure, symptoms of Crohn’s disease, opioid induced constipation, familial a...

American Heartworm Society

The mission of the American Heartworm Society is to lead the veterinary profession and the public in the understanding of heartworm disease. Founded during the Heartworm Symposium of 1974. The American Heartworm Society aims to further scientific progress in the study of heartworm disease, inform the membership of new developments and encourage and help pr...

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States ea...

Active Pass Pharmaceuticals

Active Pass' mission is to be the industry leader in the discovery and development of small-molecule drugs that target human ABC transporters. A family of 48 structurally-related molecular pumps, ABC transporters are targets for diseases with substantial markets including age-related macular degeneration, lipid disorders, Alzheimer's disease, and type II diabetes. Our competitive advantage derives...


More From BioPortfolio on "Study Evaluating ERB-041 in Active Crohn's Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks